Mass General Brigham and Niagen Plan a Healthy-Aging Trial

•

Healthy Aging

Share this post

On September 30, 2026, Niagen Bioscience announced a Start-Up Agreement with Mass General Brigham to begin detailed planning for a proposed healthy-aging trial. The company’s investor release said the trial would study Niagen, its nicotinamide riboside (NR) product.

The Proposed Design

According to the announcement, the proposal is for a multi-year randomized, placebo-controlled prevention trial in apparently healthy adults aged 50 and older. Mass General Brigham investigators would develop it in collaboration with Niagen’s research program.

The proposed comparison is NR against a placebo, with participants assigned at random. Its prevention focus places apparently healthy older adults at the center of the research rather than a population selected for a specific illness.

The investigators propose assessing both short-term and long-term effects. The intended scope combines clinical outcomes with measures of function and well-being. It also includes biological markers rather than relying on those markers alone.

Howard Sesso of Brigham and Women’s Hospital described the proposed hybrid design in the release. It would combine clinical, functional and wellness outcomes with biomarker assessments in subsets of participants. He said large-scale prevention trials are important for assessing how nutrition interventions affect clinically meaningful outcomes over time.

For men interested in staying active and mentally sharp, this proposed mix is relevant. It puts questions about daily capability alongside questions about blood measurements and major health events. Those are distinct areas of investigation that deserve separate attention when the study is eventually assessed.

Findings So Far

The proposed Mass General Brigham trial has reported no physiological or clinical results. The existing findings discussed here come from a separate earlier pilot.

The Earlier Pilot

A secondary evidence guide describes a 2024 randomized, placebo-controlled pilot involving 20 older adults with mild cognitive impairment. It reports these findings over 10 weeks:

Blood NAD+ rose in the NR group.
Cognitive scores remained stable.

These are different outcomes. One concerns a blood measure; the other concerns cognitive scores. Stable scores should not be recast as improved cognition.

That distinction is central to reading the proposed trial’s aims. A finding about NAD+ status answers a different question from a finding about mental performance. Neither should be substituted for the other when discussing what a study showed.

The Proposed Outcomes

Niagen’s announcement lists several areas under consideration. They form a proposed research agenda rather than a set of observed benefits:

Major health events: The proposal includes major morbidity and mortality. In plain English, these concern serious illness and death. Their inclusion would place clinical events alongside the functional and biological measures rather than making a blood reading the sole focus.
Physical activity and fatigue: Both appear among the possible outcomes. For men concerned with remaining active, these are relevant areas to watch when judging the study’s eventual scope. The useful question would be what the researchers actually measure within each area.
Cognition: Mental performance is another proposed area of assessment. It deserves its own place in the results rather than being inferred from a change in NAD+ status. Readers interested in memory or focus should look for the cognitive outcomes themselves.
Energy and sleep: The announcement includes both among the wellness measures being considered. These speak to everyday experience rather than blood chemistry alone. Their presence broadens the proposed questions beyond whether NR affects a laboratory measurement.
Biological measures: The proposal includes assessments related to biological aging, inflammation and NAD+ status. These would sit alongside the clinical and functional outcomes. The relevant interpretation would depend on what each type of assessment showed.

This is where judging biological-age claims against real health becomes useful. The proposed design brings several kinds of evidence into the same project. Reading them separately would help prevent a result in one category from becoming a claim about every other category.

Limits and Funding

Several details needed to assess the proposed study remain unsettled. The announcement does not provide:

A numerical sample size or NR dose.
A precise study duration or finalized clinical endpoints.
A start date or recruitment timeline.
A trial registration or reported regulatory approval.

Regulatory review and logistics also remain unresolved. Planning is subject to budgeting and final agreements. The release therefore does not establish that the final protocol, funding or execution arrangements are in place.

The company describes the study as envisioned to be its largest and most comprehensive Niagen trial to date. That is a statement of intention rather than a completed comparison of study sizes. A numerical enrollment target would be needed before readers could judge the planned scale more closely.

Commercial involvement also belongs in the assessment. Niagen Bioscience announced research on its own product and is collaborating with the investigators through its research program. The announcement also seeks contributions of expertise or resources from academic and nonprofit groups plus philanthropic and industry organizations.

Niagen CEO Rob Fried called the agreement “the next stage of responsible NAD+ science.” That phrase expresses the company’s view of the research program. It should be read as company framing.

The proposed age threshold does not settle how closely the eventual participants would resemble active men after midlife. The announcement does not specify detailed eligibility criteria or how training, health status or starting function would be handled.

The earlier pilot has a separate limitation: it involved a small group with mild cognitive impairment and short follow-up. Its findings should not be used to predict the outcome of a multi-year prevention trial in apparently healthy adults.

The Practical Takeaway

For men following research on staying capable with age, the next useful development is a finalized protocol. That would make it possible to assess who would participate and which outcomes would take priority.

The practical approach is to keep the research questions separate. A report about NAD+ status should be read for what it measured. A report about cognition or physical activity should be assessed on those outcomes rather than borrowing support from a different measurement.

When further announcements appear, look for a clear progression from planning to an agreed study design and then to reported results. Sample size and follow-up would clarify the project’s scale. Final endpoints would show how the broad list of possible outcomes has been narrowed into questions the investigators intend to answer.

This announcement is a reason to follow the research rather than change supplement use on its own. Questions about an individual’s supplement use belong with a qualified health professional. An agreement to plan research does not answer those personal questions.

What this changes: the agreement establishes a research-planning milestone rather than evidence that current best practices should change.

How Everfitguys helps

NR trial plans can be mistaken for proof of healthier aging, so Everfitguys separates research aims from evidence of benefit. Its reporting is written for men 45 and older who question longevity promises and want a clearer understanding of the evidence relevant to remaining strong and independent.

Read the research